Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002, 46: 2287-2293. 10.1002/art.10524.
Article
PubMed
Google Scholar
Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA: The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008, 35: 387-393.
PubMed
Google Scholar
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295: 2275-2285. 10.1001/jama.295.19.2275.
Article
CAS
PubMed
Google Scholar
Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ: Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007, 56: 2896-2904. 10.1002/art.22808.
Article
PubMed Central
CAS
PubMed
Google Scholar
Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med. 1993, 177: 165-173. 10.1084/jem.177.1.165.
Article
CAS
PubMed
Google Scholar
Moreland LW, Alten R, Bosch Van den F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002, 46: 1470-1479. 10.1002/art.10294.
Article
CAS
PubMed
Google Scholar
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003, 349: 1907-1915. 10.1056/NEJMoa035075.
Article
CAS
PubMed
Google Scholar
Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005, 52: 2263-2271. 10.1002/art.21201.
Article
CAS
PubMed
Google Scholar
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005, 353: 1114-1123. 10.1056/NEJMoa050524.
Article
CAS
PubMed
Google Scholar
Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006, 144: 865-876.
Article
CAS
PubMed
Google Scholar
Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006, 54: 2807-2816. 10.1002/art.22070.
Article
CAS
PubMed
Google Scholar
Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M: Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008, 67: 547-554. 10.1136/ard.2007.074773.
Article
CAS
PubMed
Google Scholar
Simon TA, Smitten AL, Meng M, Franklin J, Askling J, Lacaille D, Wolfe F, Suissa S, Hochberg M: Observed and expected hospitalized infections in the abatacept clinical development program: An updated epidemiological assessment. American College of Rheumatology, November; Boston, Massachusetts. 2007, FRI 821/849
Google Scholar
Simon TA, Covucci A, Meng M, Skovron ML: Descriptive overtime analysis of infections and malignancies in the abatacept clinical development program. American College of Rheumatology; November; Boston, Massachusetts. 2007, FRI 1039/1271
Google Scholar
Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008, 67: 1096-1103. 10.1136/ard.2007.080002.
Article
PubMed Central
CAS
PubMed
Google Scholar
Schiff M, Pritchard C, Zhou X, Bahrt K, Genovese MC: The efficacy of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: The ARRIVE trial. Arthritis Rheum. 2007, 56: S391. Abstract 942
Symmons DP, Silman AJ: The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol. 2003, 21: S94-99.
CAS
PubMed
Google Scholar
Lacaille D, Anis AH, Guh DP, Esdaile JM: Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum. 2005, 53: 241-248. 10.1002/art.21077.
Article
PubMed
Google Scholar
Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, Lindblad S, Klareskog L: Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis. 2006, 65: 707-712. 10.1136/ard.2005.045872.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wolfe F, Caplan L, Michaud K: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006, 54: 628-634. 10.1002/art.21568.
Article
CAS
PubMed
Google Scholar
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.
Article
CAS
PubMed
Google Scholar
Wilson EB, Hilferty MM: The distribution of chi-square. Proc Nat Acad Sci. 1931, 17: 684-688. 10.1073/pnas.17.12.684.
Article
PubMed Central
CAS
PubMed
Google Scholar
Salliot C, Dougados M, Gossec L: Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009, 68: 25-32. 10.1136/ard.2007.083188.
Article
PubMed Central
CAS
PubMed
Google Scholar
Dobloug JH, Forre O, Kvien TK, Egeland T, Degre M: Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Ann Rheum Dis. 1982, 41: 490-494. 10.1136/ard.41.5.490.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fox RI, Fong S, Tsoukas C, Vaughan JH: Characterization of recirculating lymphocytes in rheumatoid arthritis patients: selective deficiency of natural killer cells in thoracic duct lymph. J Immunol. 1984, 132: 2883-2887.
CAS
PubMed
Google Scholar
Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM: T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA. 2000, 97: 9203-9208. 10.1073/pnas.97.16.9203.
Article
PubMed Central
CAS
PubMed
Google Scholar
Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989, 11: 954-963.
Article
CAS
PubMed
Google Scholar
Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002, 46: 2294-2300. 10.1002/art.10529.
Article
PubMed
Google Scholar
Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM: Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008, 59: 1074-1081. 10.1002/art.23913.
Article
PubMed
Google Scholar
Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, et al: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005, 52: 3403-3412. 10.1002/art.21386.
Article
CAS
PubMed
Google Scholar
Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C: Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007, 56: 4226-4227. 10.1002/art.23050.
Article
PubMed Central
PubMed
Google Scholar
Askling J, Dixon W: The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol. 2008, 20: 138-144. 10.1097/BOR.0b013e3282f4b392.
Article
CAS
PubMed
Google Scholar
Food and Drug Administration. Guidance for Industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. [http://www.fda.gov/cber/gdlns/pharmacovig.htm]
Solomon DH: The comparative safety and effectiveness of TNF-alpha antagonists. J Manag Care Pharm. 2007, 13: S7-18.
PubMed
Google Scholar